



AMDL Contact:
Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@amd.com
(206) 310-5323

RUDD REPORT GIVES AMDL STRONG BUY RECOMMENDATION IN YEAR-END FINANCIAL RESEARCH REPORT

January 6, 2009 – (www.amdl.com) AMDL, Inc. (Amex: ADL - News), a vertically integrated pharmaceutical company with major operations in China and the US, announced today industry analyst [Lauren Rudd](#) has issued a strong buy recommendation for AMDL in his year-end financial research report on the Company.

The report projects a 12-month target price of \$5.00 for AMDL and highlights the Company's:

- Consistent, positive historical financial performance over the past four years
- Most recent operational changes and business updates, including an updated overview of AMDL's China-based subsidiary Jade Pharmaceuticals, Inc.
- FY2009 product pipeline
- FY2009 plans for the AMDL ELISA DR-70® (FDP) cancer monitoring test; best-selling Human Placenta Extract (HPE) anti-aging product line; and MYHPV Chip® diagnostic test kit which detects approximately 28 different strains of the Human Papilloma Virus.

The research report also provides a thorough peer group comparison with valuation analyses, views and opinions on AMDL's projected financial performance for the 2009 fiscal year, and historical financials.

According to Mr. Rudd, "AMDL has taken major initiatives to build its strengths while reorganizing top management and still producing respectable financials which has resulted in AMDL being one of the most under priced stocks we have seen in a long time."

A full copy of the report is available for downloading online at www.theruddreport.com or by contacting Ms. Kristine Szarkowitz, AMDL's Director Investor Relations, at kszarkowitz@amd.com.

About AMDL: More information about AMDL and its products can be obtained at www.amdl.com. AMDL, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products.

About Jade Pharmaceuticals Inc.: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its Jade subsidiaries, currently holds licenses for 133

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

AMDL, Inc.
2492 Walnut Ave., Suite 100, Tustin, CA 92780
Phone 714.505.4460 FAX 714.505.4464
Web site: <http://www.amdl.com> E-mail address: info@amd.com



AMDL Contact:

Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@amdl.com
(206) 310-5323

products that are manufactured as large volume injection fluids, tablets and other related products. It currently manufactures over 20 key generic, over-the-counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

AMDL, Inc.

2492 Walnut Ave., Suite 100, Tustin, CA 92780

Phone 714.505.4460

FAX 714.505.4464

Web site: <http://www.amdl.com>

E-mail address: info@amdl.com